| Name | Title | Contact Details |
|---|
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tjoapack is a contract packaging organisation which specialises in developing innovative primary & secondary packaging solutions for the pharma supply chain.
Western Slope Labs is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.